Final Programme - iuphar

More documents

Recommendations

Info

FC15 Endothelium in health and disease Organized by the British Pharmacological Society Leaders: Christopher J Garland, (UK) & Arthur Weston, (UK) FC15.4 Drug development and novel therapeutic targets and approaches Chairs: Johannes-Peter Stasch, (Germany) & Harald Schmidt, (The Netherlands) 09:30 - 09:55 FC15.4.1 Stimulators and activators of soluble guanylate cyclase: From bench to bedside Johannes-Peter Stasch, (Germany) 09:55 - 10:20 FC15.4.2 Gaseous signalling molecules: the biological effects of hydrogen sulfide – comparison with nitric oxide Csaba Szabó, (USA) 10:20 - 10:45 FC15.4.3 Therapeutic effects of enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling Ulrich Förstermann, (Germany), H Li 10:45 - 11:15 COFFEE BREAK 11:15 - 11:40 FC15.4.4 NOX 1, 2, 3 and counting: targeting oxidative stress Harald Schmidt, (The Netherlands), K Wingler, C Kleinschnitz 11:40 - 11:55 FC15.4.5 Free Communication Presentation: Effects of K + channel blockers on the relaxation induced by nitric oxide (NO) donors in basilar artery from renal hypertensive 2K-1C rats Michele Paulo, (Brazil), J Vercesi, J Biazzotto, R da Silva, L Bendhack 11:55 - 12:10 FC15.4.6 Free Communication Presentation: MicroRNA-27b rescues impaired endothelial progenitor cell-induced angiogenesis and wound healing via suppressing thrombospondin-1 in type 2 diabetes Alex Chen, (USA), J Wang, 12:10 - 12:25 FC15.4.7 Free Communication Presentation: Co-activation of PKCdelta/ERK1/2 and p38 MAPK mediates angiotensin II-induced cyclooxygenase-2 up-regulation in endothelial cells and the clinical implications Siu Ling Wong, (PR China), CW Lau, WT Wong, A Xu, CL Au, X Yao, Y Huang 154 Friday 23 July ■ 09:30 - 12:30 ■ Hall A3
FC16 Natural products: Past and future? Organized by the IUPHAR Section on the Pharmacology of Natural Products Leaders: Ricky Ying-Keung Man, (PR China), Tai-Ping Fan, (UK) & Zhi-bin Lin, (PR China) FC16.5 Globalization of natural/traditional products Chairs: Ricky Ying-Keung Man, (PR China) & Monique Simmonds, (UK) 09:30 - 09:55 FC16.5.1 Geographical sustainability of natural products: As modelled by the Araliaceae family Yuri N Zhuravlev, (Russian Federation) 09:55 - 10:20 FC16.5.2 Authentication of natural products Monique Simmonds, (UK) 10:20 - 10:45 FC16.5.3 Standardization of natural products (chemical and biological finger printing) Y-C Cheng, Robert Tilton, (USA) 10:45 - 11:15 COFFEE BREAK 11:15 - 11:40 FC16.5.4 Challenges in research on natural products and dietary supplements Josephine P Briggs, (USA) 11:40 - 11:55 FC16.5.5 Free Communication Presentation: Studies on the ADME/Tox characteristics of Xiao Chai Hu Tang in Caco-2 cell model Jun-Ning Zhao, (PR China), L-C Yan, Q-C Liu, Y-Q Bi, J-H Yi 11:55 - 12:10 General discussion Friday 23 July ■ 09:30 - 12:15 ■ Auditorium 15 155
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
FC01 Clinical pharmacology in the e
Page 66 and 67:
FC03 Ion channels in analgesia and
Page 68 and 69:
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107: W23 Workshop. Applying pharmacogeno
Page 108 and 109: W25 Workshop. High science in the l
Page 110 and 111: W27 Workshop. Approaches to medicin
Page 112 and 113: FC11 G protein-coupled 7TM receptor
Page 114 and 115: FC13 Maximising benefits and minimi
Page 116 and 117: FC15 Endothelium in Health and dise
Page 118 and 119: FC17 New approaches and targets in
Page 120 and 121: FC18 Nuclear receptor targets for t
Page 122 and 123: PL16 Plenary Lecture Supported by a
Page 128 and 129: FC15 Endothelium in Health and dise
Page 132 and 133: W28 Workshop. The Boehringer-Ingelh
Page 134 and 135: W30 Workshop. Is eNOS still a valid
Page 136 and 137: W32 Workshop. The good, the bad and
Page 138 and 139: W34 Workshop. State-of-the-art of b
Page 140 and 141: FC10 Drugs for half the world: Pedi
Page 142 and 143: FC12 Ion channelopathies: New windo
Page 144 and 145: FC14 Addiction and doping: Neurobio
Page 146 and 147: FC16 Natural products: Past and fut
Page 148 and 149: FC18 Nuclear receptor targets for t
Page 150 and 151: PL22 Plenary Lecture Chair: Zhi-Bin
Page 160 and 161: 158
Page 162 and 163: FC01 Clinical pharmacology in the e
Page 166 and 167: FC02 Transmembrane transport: Persp
Page 168 and 169: FC03 Ion channels in analgesia and
Page 170 and 171: W12 Experimental pain methods in de
Page 172 and 173: FC04 Pharmacoepidemiology, current
Page 174 and 175: FC05 Translational science in the m
Page 176 and 177: FC05 Translational science in the m
Page 178 and 179: FC06 The heart gone wrong; stabiliz
Page 180 and 181: FC07 Simulation and data modelling
Page 182 and 183: FC08 Developments in the treatment
Page 184 and 185: FC09 Inflammation and immunopharmac
Page 194 and 195: W03 Targeting TRP channels for pain
Page 196 and 197: W19 Influence of degeneration and r
Page 198 and 199: W19 Influence of degeneration and r
Page 200 and 201: W20 Pharmacology education for a su
Page 204 and 205: FC02 Transmembrane transport: Persp
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
FC07 Simulation and data modelling
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
FC13 Maximising benefits and minimi
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
FC11 G protein-coupled 7TM receptor
Page 252 and 253:
Page 254 and 255:
FC12 Ion channelopathies: New windo
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
FC15 Endothelium in health and dise
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
FC16 Natural products: Past and fut
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
FC18 Nuclear receptor targets for t
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

Create successful ePaper yourself

Delete template?

Save as template?